BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

CAMBRIDGE, Mass. & BEIJING & MOSCOW–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene and Nanolek announce BRUKINSA® (zanubrutinib) approval in Russia for treatment of patients with relapsed or refractory mantle cell lymphoma.
Click here to view original post